DANIEL PINA: Open Payments
NPI 1720479884 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$944 in 49 payments from 13 companies in 2025. Trend: 2023 $1,508 · 2024 $842 · 2025 $944
Food & beverage: $944
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $196 |
| AstraZeneca Pharmaceuticals LP | 4 | $185 |
| ABBVIE INC. | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Abbott Laboratories | 3 | $86 |
| Lilly USA, LLC | 4 | $75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| PFIZER INC. | 1 | $23 |
Products named: FARXIGA, JARDIANCE, REXULTI, LINZESS, Rybelsus, Ozempic, PROCLAIM, Wegovy.
Industry payments across TX — which companies pay providers there.
